NeuBase Therapeutics’ (NBSE) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of NeuBase Therapeutics (NASDAQ:NBSE) in a report released on Monday, AnalystRatings.com reports. HC Wainwright currently has a $14.00 price objective on the stock.
Several other analysts also recently issued reports on the company. Oppenheimer assumed coverage on NeuBase Therapeutics in a research note on Wednesday, November 20th. They issued an outperform rating and a $14.00 price target on the stock. ValuEngine lowered NeuBase Therapeutics from a hold rating to a sell rating in a report on Wednesday, November 20th. Finally, BTIG Research began coverage on NeuBase Therapeutics in a research report on Tuesday, September 24th. They set a buy rating and a $15.00 price objective for the company.
NBSE opened at $7.29 on Monday. NeuBase T ...